Publications

BibTex format

@article{Zhang:2023:10.1021/acs.nanolett.2c04883,
author = {Zhang, Y and Yan, J and Hou, X and Wang, C and Kang, DD and Xue, Y and Du, S and Deng, B and McComb, DW and Liu, S-L and Zhong, Y and Dong, Y},
doi = {10.1021/acs.nanolett.2c04883},
journal = {Nano Lett},
pages = {2593--2600},
title = {STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2.},
url = {http://dx.doi.org/10.1021/acs.nanolett.2c04883},
volume = {23},
year = {2023}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Lipid nanoparticle (LNP)-mediated delivery of messenger RNA (mRNA) COVID-19 vaccines has provided large-scale immune protection to the public. To elicit a robust immune response against SARS-CoV-2 infections, antigens produced by mRNAs encoding SARS-CoV-2 Spike glycoprotein need to be efficiently delivered and presented to antigen-presenting cells such as dendritic cells (DCs). As concurrent innate immune stimulation can facilitate the antigen presentation process, a library of non-nucleotide STING agonist-derived amino lipids (SALs) was synthesized and formulated into LNPs for mRNA delivery. SAL12 lipid nanoparticles (SAL12-LNPs) were identified as most potent in delivering mRNAs encoding the Spike glycoprotein (S) of SARS-CoV-2 while activating the STING pathway in DCs. Two doses of SAL12 S-LNPs by intramuscular immunization elicited potent neutralizing antibodies against SARS-CoV-2 in mice.
AU  - Zhang,Y
AU  - Yan,J
AU  - Hou,X
AU  - Wang,C
AU  - Kang,DD
AU  - Xue,Y
AU  - Du,S
AU  - Deng,B
AU  - McComb,DW
AU  - Liu,S-L
AU  - Zhong,Y
AU  - Dong,Y
DO  - 10.1021/acs.nanolett.2c04883
EP  - 2600
PY  - 2023///
SP  - 2593
TI  - STING Agonist-Derived LNP-mRNA Vaccine Enhances Protective Immunity Against SARS-CoV-2.
T2  - Nano Lett
UR  - http://dx.doi.org/10.1021/acs.nanolett.2c04883
UR  - https://www.ncbi.nlm.nih.gov/pubmed/36942873
VL  - 23
ER  -

Download

Professor David W. McComb

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)